Cargando…

Urothelial carcinoma of donor origin in a kidney transplant patient

BACKGROUND: Malignancy after transplantation is an uncommon multifactorial occurrence. Immunosuppression to prevent graft rejection is described as a major risk factor in malignancy development in the post-transplant state. Donor-derived malignancy is a rare reported complication. Herein, we review...

Descripción completa

Detalles Bibliográficos
Autores principales: Michel Ortega, Rosa M., Wolff, Daynna J., Schandl, Cynthia A., Drabkin, Harry A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067888/
https://www.ncbi.nlm.nih.gov/pubmed/27777772
http://dx.doi.org/10.1186/s40425-016-0167-4
_version_ 1782460725006958592
author Michel Ortega, Rosa M.
Wolff, Daynna J.
Schandl, Cynthia A.
Drabkin, Harry A.
author_facet Michel Ortega, Rosa M.
Wolff, Daynna J.
Schandl, Cynthia A.
Drabkin, Harry A.
author_sort Michel Ortega, Rosa M.
collection PubMed
description BACKGROUND: Malignancy after transplantation is an uncommon multifactorial occurrence. Immunosuppression to prevent graft rejection is described as a major risk factor in malignancy development in the post-transplant state. Donor-derived malignancy is a rare reported complication. Herein, we review our patient history and discuss diagnostic strategies and the implications of immunosuppression for donor-derived malignancy. CASE PRESENTATION: This is a 69-year-old man with post-renal-transplant urothelial carcinoma determined to be of donor origin. His course was complicated by BK virus at six years post-transplant; urothelial carcinoma was identified nine years post-transplant. Cystectomy was performed, but because of immunosuppression and underlying chronic kidney disease, the patient was considered ineligible for adjuvant chemotherapy. Two years after resection, screening MRI demonstrated retroperitoneal lymphadenopathy and a right upper pole mass in the transplanted kidney. Urine cytology confirmed the presence of malignant cells; FISH showed 2-8 copies of the X chromosome and no Y chromosome consistent with female origin of the malignant cells. CT-guided renal mass and paraaortic lymph node biopsies demonstrated that about 50 % of cells had an XY complement, while the remainder showed a XX genotype by chromosomal SNP microarray analysis. Immunosuppression was discontinued and the donor kidney removed. X/Y FISH of the urothelial carcinoma identified in the explanted kidney confirmed that the malignant cells were of female donor origin. Follow-up at 3, 6 and 12 months after discontinuation of immunosuppression and surgery demonstrated normalization of the lymphadenopathy and absence of new lesions. CONCLUSIONS: Immunosuppression is a major risk factor for development of malignancy in transplant recipients. Donor-derived malignancy can arise and current molecular studies allow an accurate diagnosis. Withdrawal of immunosuppression and surgical resection of the transplant kidney proved an effective treatment in our case.
format Online
Article
Text
id pubmed-5067888
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50678882016-10-24 Urothelial carcinoma of donor origin in a kidney transplant patient Michel Ortega, Rosa M. Wolff, Daynna J. Schandl, Cynthia A. Drabkin, Harry A. J Immunother Cancer Case Report BACKGROUND: Malignancy after transplantation is an uncommon multifactorial occurrence. Immunosuppression to prevent graft rejection is described as a major risk factor in malignancy development in the post-transplant state. Donor-derived malignancy is a rare reported complication. Herein, we review our patient history and discuss diagnostic strategies and the implications of immunosuppression for donor-derived malignancy. CASE PRESENTATION: This is a 69-year-old man with post-renal-transplant urothelial carcinoma determined to be of donor origin. His course was complicated by BK virus at six years post-transplant; urothelial carcinoma was identified nine years post-transplant. Cystectomy was performed, but because of immunosuppression and underlying chronic kidney disease, the patient was considered ineligible for adjuvant chemotherapy. Two years after resection, screening MRI demonstrated retroperitoneal lymphadenopathy and a right upper pole mass in the transplanted kidney. Urine cytology confirmed the presence of malignant cells; FISH showed 2-8 copies of the X chromosome and no Y chromosome consistent with female origin of the malignant cells. CT-guided renal mass and paraaortic lymph node biopsies demonstrated that about 50 % of cells had an XY complement, while the remainder showed a XX genotype by chromosomal SNP microarray analysis. Immunosuppression was discontinued and the donor kidney removed. X/Y FISH of the urothelial carcinoma identified in the explanted kidney confirmed that the malignant cells were of female donor origin. Follow-up at 3, 6 and 12 months after discontinuation of immunosuppression and surgery demonstrated normalization of the lymphadenopathy and absence of new lesions. CONCLUSIONS: Immunosuppression is a major risk factor for development of malignancy in transplant recipients. Donor-derived malignancy can arise and current molecular studies allow an accurate diagnosis. Withdrawal of immunosuppression and surgical resection of the transplant kidney proved an effective treatment in our case. BioMed Central 2016-10-18 /pmc/articles/PMC5067888/ /pubmed/27777772 http://dx.doi.org/10.1186/s40425-016-0167-4 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Michel Ortega, Rosa M.
Wolff, Daynna J.
Schandl, Cynthia A.
Drabkin, Harry A.
Urothelial carcinoma of donor origin in a kidney transplant patient
title Urothelial carcinoma of donor origin in a kidney transplant patient
title_full Urothelial carcinoma of donor origin in a kidney transplant patient
title_fullStr Urothelial carcinoma of donor origin in a kidney transplant patient
title_full_unstemmed Urothelial carcinoma of donor origin in a kidney transplant patient
title_short Urothelial carcinoma of donor origin in a kidney transplant patient
title_sort urothelial carcinoma of donor origin in a kidney transplant patient
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067888/
https://www.ncbi.nlm.nih.gov/pubmed/27777772
http://dx.doi.org/10.1186/s40425-016-0167-4
work_keys_str_mv AT michelortegarosam urothelialcarcinomaofdonororigininakidneytransplantpatient
AT wolffdaynnaj urothelialcarcinomaofdonororigininakidneytransplantpatient
AT schandlcynthiaa urothelialcarcinomaofdonororigininakidneytransplantpatient
AT drabkinharrya urothelialcarcinomaofdonororigininakidneytransplantpatient